MarketLens
Sign Up

Fairmount Funds' $12 Million Bet on Crescent Biopharma: A Strong Signal Amidst Volatility

2 months ago
SHARE THIS ON:

Fairmount Funds' $12 Million Bet on Crescent Biopharma: A Strong Signal Amidst Volatility

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News5 days ago

Investor Determination to Beat Cancer Puts NeOnc's Novel Therapies and Patented Platform in Focus

NeOnc CEO bought 37,000 more shares after a $15M financing with healthcare-focused institutions, signaling confidence in the company's novel cancer therapies and patented platform.
Stock News1 months ago

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Small-cap biotech stocks are rallying as macro and policy headwinds ease, with FDA stabilization and a resurgence in M&A and IPO activity restoring capital flows and investor confidence.
Stock News2 months ago

Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma priced an underwritten public offering of ~8.6M shares and pre-funded warrants. The capital raise dilutes existing holders and signals near-term cash needs for its clinical-stage pi...

Breaking News

View All →

Top Headlines

View More →
Stock News47 minutes ago

Prediction: Nvidia's Revenue Growth Will Drive Shares to $400 Next Year

Stock News1 hour ago

Bill Ackman Built a $2.4 Billion Stake in Microsoft, Calling It a "Core Holding" Bought at a "Highly Compelling Valuation." Here's Why He's Betting Big on Big Tech.

Stock News2 hours ago

The Stock Market's Best Quarter of the Year Is About to Start. The S&P 500 Has Risen in 34 of the Last 41.

Stock News4 hours ago

Nvidia's Jensen Huang says AI CEOs have 'ulterior reasons' for warning about doomsday

Stock News6 hours ago

Meta's Muse TV ad is the latest sign that AI agents are going mainstream